Results 41 to 50 of about 52,371 (280)

B2M drives PD-1 inhibitor resistance in DLBCL through independent dual immune escape mechanisms

Open Life Sciences
PD-1/PD-L1 immune checkpoint inhibitors (ICIs) demonstrate promising therapeutic potential in diffuse large B-cell lymphoma (DLBCL). However, a subset of DLBCL patients exhibits primary or acquired resistance to PD-1 blockade. This study investigated the
Liu Ying, Xu Xiao, Li Chengtian, Mou Shangdong, Wang Feifei, Yao Zhongqiang, Chen Qingjuan   +6 more
doaj   +1 more source

Clinical and Prognostic Value of Molecular Markers of Diffuse Large B-Cell Lymphoma

Клиническая онкогематология, 2019
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid tumor in adults which is associated with approximately 30–40 % of all non-Hodgkin’s lymphomas.
S. M. Rastorguev, D. A. Koroleva, E. S. Boulygina, S. V. Tsygankova, N. G. Goncharov, O. S. Naraikin, N. G. Gabeeva, E. E. Zvonkov, A. V. Nedoluzhko   +8 more
doaj   +1 more source

Correlation between Germinal Center Differentiation and Double/Triple Hit Score in the Classification of Diffuse Large B Cell Non-Hodgkin Lymphoma: A Clinicopathological Approach

Asian Pacific Journal of Cancer Care, 2023
Background: Diffuse large B cell lymphoma (DLBCL) is considered the most common type of non-Hodgkin lymphoma. The global incidence of DLBCL has been doubled in the past decades, highlighting the need for more effective treatment regimens.
Israa Sobhy Abdel Razek Okap, Hanan Yehia Ahmed Tayel, Amany Abd El-Bary Abd El-Latif, Dalia Ahmed Mohamed Nafea, Nagwa Abdel Razek Mashali   +4 more
doaj   +1 more source

MYC in DLBCL: partners matter [PDF]

Blood, 2015
In this issue of Blood, Copie-Bergman et al demonstrate that MYC rearrangements (MYC-Rs) with IG genes, but not with other partner genes, have a negative prognostic impact in patients with diffuse large B-cell lymphomas (DLBCLs) treated with immunochemotherapy.
openaire   +2 more sources

Model‐informed optimal dose selection of golcadomide in combination with R‐CHOP in patients with previously untreated aggressive B‐cell lymphoma

British Journal of Clinical Pharmacology, EarlyView.
Aims Golcadomide is a potential first‐in‐class oral CELMoD™ agent for the treatment of lymphoma. This study aims to develop model‐informed drug development (MIDD) approaches to support optimal dose selection of golcadomide in combination with immunotherapy rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) in alignment with ...
Xirong Zheng, Zhiling Yu, Mark Kaplan, Argyrios Gkasiamis, Akshay Sudhindra, Li Zhu, Manisha Lamba, Fan Wu   +7 more
wiley   +1 more source

Primary diffuse large B-cell lymphoma at gastrojejunostomy site: A rare case report

Medical Journal of Dr. D.Y. Patil Vidyapeeth, 2023
The occurrence of lymphoma at the gastrojejunostomy (GJ) site is infrequent. Only two GJ site lymphoma cases are reported in the literature. Endoscopy and biopsy are primary methods for diagnosis which should be performed in these patients for the exact ...
Shruthi, H L Kishan Prasad, K Sajitha, Lancelot Lobo   +3 more
doaj   +1 more source

Risk of Bias Associated with Varying Sampling Strategies for External Comparator Cohorts for Single‐Arm Trials: Insights from Aggressive Lymphoma

Clinical Pharmacology &Therapeutics, EarlyView.
Marketing authorizations for oncology drugs are often based on single‐arm trials (SATs), and real‐world data‐based external comparator cohorts (ECCs) are increasingly explored to contextualize results. In retrospective studies, comparators may be identified by time of diagnosis but included based on time of relapse; such sampling strategies can ...
Mikkel Runason Simonsen, Shiva Leisner, Ahmed Ludvigsen Al‐Mashhadi, Laurids Østergaard Poulsen, Matthew Maurer, Lasse Hjort Jakobsen, Tarec Christoffer El‐Galaly   +6 more
wiley   +1 more source

Value of CD5 and CD79 in Evaluation of GIT Lymphoma

Medical Journal of Babylon
Background: Primary gastrointestinal lymphoma is a rare tumor, accounting for less than 5% of all GIT lymphoma, 10%–15% of all non-Hodgkin lymphoma, and encompasses 30%–40% of total extranodal lymphoma its incidence is increasing.
Huda Mohammed Abdulwahid, Haider AbdulRidha Alkafaji, Zainab Wehab Al Maaroof   +2 more
doaj   +1 more source

CD19-Directed CAR T Cells Treatment in a Patient with Refractory DLBCL and CNS Involvement

healthbook TIMES. Oncology Hematology, 2019
Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common neoplasm of the lymphatic system. Treatment and clinical management are difficult in the relapsed/refractory (R/R) setting.
Antonia Maria S. Müller, Alexander Ring
doaj   +1 more source

The Impact of Age and Sex in DLBCL: Systems Biology Analyses Identify Distinct Molecular Changes and Signaling Networks

, 2015
Potential molecular alterations based on age and sex are not well defined in diffuse large B-cell lymphoma (DLBCL). We examined global transcriptome DLBCL data from The Cancer Genome Atlas (TCGA) via a systems biology approach to determine the molecular ...
Neuberg, Donna, Beheshti, Afshin, Donna Neuberg, McDonald, J. Tyson, Vanderburg, Charles, J. Tyson McDonald, Andrew M. Evens, Evens, Andrew M., Afshin Beheshti, Charles R. Vanderburg   +9 more
core   +1 more source